|
|
|
|
|
|
Sponsored by: |
Case Comprehensive Cancer Center |
Information provided by: | National Cancer Institute (NCI) |
ClinicalTrials.gov Identifier: | NCT00403169 |
RATIONALE: Lenalidomide may stop the growth of kidney cancer by blocking blood flow to the tumor.
PURPOSE: This phase II trial is studying how well lenalidomide works in treating patients with advanced or unresectable kidney cancer.
Condition | Intervention | Phase |
Kidney Cancer |
Drug: lenalidomide |
Phase II |
MedlinePlus related topics: | Cancer Kidney Cancer |
ChemIDplus related topics: | Lenalidomide CC 5013 |
Study Type: | Interventional |
Study Design: | Treatment, Open Label |
Official Title: | Phase II Study of CC-5013 in Patients With Advanced Renal Cell Carcinoma (RCC) |
Estimated Enrollment: | 26 |
Study Start Date: | August 2004 |
OBJECTIVES:
OUTLINE: This is an open-label study.
Patients receive oral lenalidomide daily on days 1-21. Courses repeat every 28 days in the absence of unacceptable toxicity or disease progression.
After completion of study treatment, patients are followed every 3 months.
PROJECTED ACCRUAL: A total of 26 patients will be accrued for this study.
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
DISEASE CHARACTERISTICS:
Histologically or cytologically confirmed renal cell carcinoma (RCC)
No brain metastases
PATIENT CHARACTERISTICS:
No uncontrolled intercurrent illness including, but not limited to, any of the following:
PRIOR CONCURRENT THERAPY:
United States, Ohio | |||||
Case Comprehensive Cancer Center | |||||
Cleveland, Ohio, United States, 44106-5065 |
Case Comprehensive Cancer Center |
Study Chair: | Ronald M. Bukowski, MD | Case Comprehensive Cancer Center |
Clinical trial summary from the National Cancer Institute's PDQ® database 
  |
Study ID Numbers: | CDR0000446094, CASE-CCF-7165 |
First Received: | November 21, 2006 |
Last Updated: | July 23, 2008 |
ClinicalTrials.gov Identifier: | NCT00403169 |
Health Authority: | United States: Food and Drug Administration |
|
|
|
|
|